Cost and Use of Medical Devices in Incident Early-Onset Myasthenia Gravis Patients in France
Author(s)
CECILE BLEIN, PhD1, Shahram Attarian, MD, Pr2, Jean-Philippe Camdessanche, MD, Pr3, Guilhem SOLE, MD4, Mariana CIUMAS, PhD5, Andoni ECHANIZ-LAGUNA, MD6;
1Argenx, DIRECTOR RWE, Zwijnaarde, Belgium, 2APHM, Neurology, MARSEILLE, France, 3Hôpital Nord, University Hospital of Saint-Étienne, ST ETIENNE, France, 4Pellegrin Hospital, Bordeaux, Neurology, BORDEAUX, France, 5argenx, GHENT, Belgium, 6APHP, Neurology, PARIS, France
1Argenx, DIRECTOR RWE, Zwijnaarde, Belgium, 2APHM, Neurology, MARSEILLE, France, 3Hôpital Nord, University Hospital of Saint-Étienne, ST ETIENNE, France, 4Pellegrin Hospital, Bordeaux, Neurology, BORDEAUX, France, 5argenx, GHENT, Belgium, 6APHP, Neurology, PARIS, France
Presentation Documents
OBJECTIVES: To assess the use and cost of medical devices (MDs) over time in incident early-onset myasthenia gravis (MG) patients compared to the overall MG cohort.
METHODS: A retrospective, longitudinal cohort study was conducted using the French national health insurance claims database (SNDS) from January 2013 to December 2020. Early-onset MG patients, defined as those with MG onset before the age of 50, were identified. The use and costs of medical devices (MD) were assessed during the 5 years of follow-up period, with comparisons to the overall incident MG cohort.
RESULTS: Among 14,459 MG patients, 3,505 had early-onset MG (mean age: 36.5 years, SD 8.59; 70% female) of whom 1,802 were incident early onset MG (mean age: 35.7 years, SD 8.94; 66% female) . Incident early-onset MG patients had a lower CCI score (0.30) compared to the overall MG cohort (2.73), with fewer comorbidities such as cerebrovascular disease, depression, and asthma/COPD. MD use was high in early-onset patients: 91% of patients received an MD prescription during follow-up, with 69% prescribed within the first year. The average annual MD per patient use increased from 6 devices at baseline to 8 by year 5. MD costs per patient rose from €388 in year 1 to €750 in year 5, representing a 93% increase. In comparison, the incident MG cohort showed a 25% increase in mean MD costs per patient, from €492 in year 1 to €615 in year 5.
CONCLUSIONS: Incident early-onset MG patients despite having fewer comorbidities, exhibit high MD usage and rapidly rising costs, particularly in the first year post-diagnosis. MD costs increase over time, highlighting the need for continued support and optimized care strategies for this subgroup. These findings underscore the importance of early interventions to improve long-term outcomes and reduce disease burden in early-onset MG.
METHODS: A retrospective, longitudinal cohort study was conducted using the French national health insurance claims database (SNDS) from January 2013 to December 2020. Early-onset MG patients, defined as those with MG onset before the age of 50, were identified. The use and costs of medical devices (MD) were assessed during the 5 years of follow-up period, with comparisons to the overall incident MG cohort.
RESULTS: Among 14,459 MG patients, 3,505 had early-onset MG (mean age: 36.5 years, SD 8.59; 70% female) of whom 1,802 were incident early onset MG (mean age: 35.7 years, SD 8.94; 66% female) . Incident early-onset MG patients had a lower CCI score (0.30) compared to the overall MG cohort (2.73), with fewer comorbidities such as cerebrovascular disease, depression, and asthma/COPD. MD use was high in early-onset patients: 91% of patients received an MD prescription during follow-up, with 69% prescribed within the first year. The average annual MD per patient use increased from 6 devices at baseline to 8 by year 5. MD costs per patient rose from €388 in year 1 to €750 in year 5, representing a 93% increase. In comparison, the incident MG cohort showed a 25% increase in mean MD costs per patient, from €492 in year 1 to €615 in year 5.
CONCLUSIONS: Incident early-onset MG patients despite having fewer comorbidities, exhibit high MD usage and rapidly rising costs, particularly in the first year post-diagnosis. MD costs increase over time, highlighting the need for continued support and optimized care strategies for this subgroup. These findings underscore the importance of early interventions to improve long-term outcomes and reduce disease burden in early-onset MG.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
EPH6
Topic
Epidemiology & Public Health
Topic Subcategory
Public Health
Disease
SDC: Neurological Disorders, SDC: Rare & Orphan Diseases